ENDRA Life Sciences Demonstrates High Consistency in TAEUS® Liver Device for MASLD Monitoring
ENDRA Life Sciences Inc , a leading innovator in thermoacoustic imaging technology, has reported highly favorable results from a recent clinical study evaluating the measurement consistency and reliability of its TAEUS® Liver device. This milestone study underscores the potential of TAEUS to transform the diagnosis and monitoring of steatotic liver disease (SLD), particularly in the context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a condition now affecting nearly 30% of adults globally. By demonstrating strong repeatability and reproducibility, ENDRA reinforces its mission to provide a practical, cost-effective alternative to traditional imaging modalities, bridging a significant gap in the early detection and management of liver disease.
The clinical study involved 14 subjects with varying degrees of liver fat accumulation, assessed under real-world clinical conditions by independent operators. Each operator performed multiple measurements on the subjects, yielding a total of 56 unique readings. The study design utilized a rigorous Gage Repeatability and Reproducibility (R&R) framework—a gold-standard methodology in medical device validation—to differentiate the variability caused by the measurement system itself from true biological differences among patients. This approach ensures that the observed outcomes reflect the device’s technical performance rather than inconsistencies due to operator differences or measurement conditions.
Results from the study were compelling. The TAEUS Liver device achieved an Intraclass Correlation Coefficient (ICC) of 0.89, alongside a Standard Error of Measurement (SEM) of 3.3%. These metrics place the system within the “Good to Excellent” range of performance, demonstrating not only reliable intra-user repeatability—meaning that the same operator can consistently reproduce measurements—but also high inter-user reproducibility, ensuring that different clinicians can obtain comparable results on the same patient. This consistency is particularly important for monitoring MASLD over time, as even small deviations in measurement can affect clinical decision-making regarding treatment efficacy and progression of liver disease.
Dr. Alexander Tokman, Chief Executive Officer of ENDRA Life Sciences, highlighted the significance of these findings, stating, “While MRI-PDFF remains the gold standard for liver fat quantification, its high cost, limited availability, and logistical constraints make frequent monitoring impractical for the more than two billion people affected by MASLD worldwide. Our new performance data, showing a 3.3% SEM and a 0.89 ICC, strongly support the belief that TAEUS can deliver reliable, consistent measurements comparable to MRI—but at the point of patient care and at a fraction of the cost.”
The implications of this technology are wide-reaching. Unlike traditional ultrasound techniques, which often suffer from subjective interpretation and high operator variability, the TAEUS system offers a standardized, objective measurement of liver fat. Conventional ultrasound has long been criticized for inconsistent results between different operators and even between successive measurements by the same clinician. TAEUS’s thermoacoustic approach addresses these challenges by combining the non-invasive convenience of ultrasound with advanced signal acquisition and processing algorithms that ensure measurement precision.
In practice, this means that physicians and healthcare systems could deploy TAEUS for routine screening and longitudinal monitoring of MASLD, even in community-based clinics or resource-limited settings. Frequent, low-cost liver fat assessment becomes feasible without the logistical and financial burden of repeated MRI scans, which are typically restricted to specialized imaging centers and can be cost-prohibitive for ongoing monitoring. For patients, this translates into more accessible care, earlier detection of disease progression, and timely intervention.
Pharmaceutical applications are another critical dimension of TAEUS’s potential. With an increasing number of metabolic therapies entering clinical trials, there is a growing need for reliable, non-invasive tools to monitor treatment response. TAEUS could play a key role in patient recruitment, baseline stratification, and follow-up assessment, enabling researchers to track even modest reductions in liver fat over time without relying on expensive and limited MRI resources. By providing objective, repeatable measurements, TAEUS may also help streamline trial design, improve endpoint accuracy, and reduce variability in multicenter studies.
The study’s methodology underscores ENDRA’s commitment to robust clinical validation. By carefully quantifying both intra- and inter-operator variability, the company ensures that the device meets stringent standards required for regulatory approval and widespread clinical adoption. Achieving a high ICC is particularly noteworthy, as it indicates that the majority of measurement variability is due to actual differences in patient liver fat rather than inconsistencies in the measurement system. Similarly, the low SEM confirms that individual measurements are precise and repeatable, reinforcing confidence in clinical decision-making.
Looking forward, ENDRA is poised to leverage these results to further advance the adoption of TAEUS in clinical practice. As awareness of MASLD grows and the demand for routine liver health monitoring increases, devices that combine precision, reliability, and affordability will become indispensable. ENDRA’s innovative TAEUS system not only meets these criteria but also exemplifies the evolving landscape of medical imaging, where advanced technology is integrated seamlessly into everyday patient care.
In conclusion, the recent study demonstrates that ENDRA Life Sciences’ TAEUS Liver device delivers consistent, reliable, and high-precision measurements of liver fat, addressing key limitations of traditional imaging techniques. By offering MRI-comparable accuracy at a lower cost and with point-of-care accessibility, TAEUS stands to redefine how MASLD is monitored and managed worldwide. This advancement represents a critical step toward broader adoption of non-invasive diagnostic tools and reflects ENDRA’s ongoing commitment to improving liver health outcomes on a global scale.
As MASLD continues to affect an increasing proportion of the population, tools like TAEUS are likely to play a pivotal role in both clinical care and research, enabling earlier interventions, more frequent monitoring, and improved patient outcomes. ENDRA’s demonstration of high measurement consistency paves the way for widespread deployment, potentially transforming the landscape of liver disease management and offering hope to millions of individuals at risk of progressive liver conditions.
